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Dietary polyunsaturated fatty acids (PUFAs) have gained more importance 
these last decades since they regulate the level of long-chain PUFAs (LC-PUFAs) in 
all cells and especially in brain cells. Because LC-PUFAs, especially those of the n-3 
family, display both anti-inflammatory and pro-resolution properties, they play an 
essential role in neuroinflammation. Neuroinflammation is a hallmark of neuro-
logical disorders and requires to be tightly controlled or at least limited otherwise 
it can have functional consequences and negatively impact the quality of life and 
well-being of patients. LC-PUFAs exert these beneficial properties in part through 
the synthesis of specialized pro-resolving mediators (SPMs) that are involved in the 
resolution of inflammation and to the return of homeostasis. SPMs are promising 
relevant candidates to resolve brain inflammation and to contribute to neuroprotec-
tive functions and lead to novel therapeutics for brain inflammatory diseases. Here 
we present an overview of the origin and accumulation of PUFAs in the brain and 
brain cells and their conversion into SPMs that are involved in neuroinflammation 
and how nutrition induces variations in LC-PUFA and SPM levels in the brain and 
in brain cells.
Keywords: long-chain polyunsaturated fatty acids (LC-PUFAs), docosahexaenoic 
acid (DHA), eicosapentaenoic acid (EPA), specialized pro-resolving mediators 
(SPMs), nutrition, neuroinflammation, brain, brain cells
1. Introduction
Polyunsaturated fatty acids (PUFA) are essential fatty acids including precur-
sors and long-chain PUFAs (LC-PUFAs). Precursors have to be provided by the 
diet because they cannot be produced by mammals [1]. They can be converted into 
LC-PUFAs. However, as the conversion rate is very low in human [2, 3], it is recom-
mended to consume also LC-PUFAs that modulate LC-PUFA composition of brain 
and brain cells. Altered dietary intake and/or PUFA metabolism has been reported 
to be involved in a number of neurological disorders via sustained neuroinflam-
matory processes [4]. Indeed, LC-PUFAs are key regulators of inflammation [5]. 
LC-PUFAs can be metabolized into specific derivatives such as specialized pro-
resolving mediators (SPMs) that have anti-inflammatory and pro-resolving proper-
ties [6–9], giving the LC-PUFAs and their biological derivatives a growing interest 
to treat inflammation and more specifically neuroinflammation. Hence, they may 
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represent a relevant alternative or complementary strategy to treat pathologies 
involving neuroinflammation. Here, we will review the literature on PUFAs and 
their bioactive lipid derivatives in the brain and brain cells. The book chapter will 
be divided in two main sections: in the first one, we will report data on the origin of 
PUFAs in the brain and on PUFA content in brain and brain cells and in the second 
one, we will review recent data on the bioactive lipid derivatives and their role in 
neuroinflammation. We will discuss how nutrition, an environmental factor to 
which individuals are exposed throughout their life, is a factor of variation of PUFA 
and their mediator contents in both sections. We will focus on total brain but also 
on brain cells since brain cells are differently affected by dietary supply.
2. PUFAs in the brain and brain cells
2.1 Origin of PUFAs in the brain
2.1.1 Metabolism of PUFAs
PUFAs are fatty acids containing more than one double bond on their carbon 
chain. They are classified into two main series, the n-6 PUFAs and the n-3 PUFAs 
depending on the position of the first double bond from the methyl terminal end. 
N-6 PUFAs have the first double bond at the 6th carbon and n-3 PUFAs at the 
3rd. Of these two series, linoleic acid (LA) and alpha-linolenic acid (ALA) are 
the precursors and are essential fatty acids because mammals cannot synthesize 
them. In vivo, these precursors can be elongated, desaturated and beta-oxidized 
into fatty acids with additional double bonds and carbon atoms leading to long-
chain PUFAs (LC-PUFAs, ≥20 carbon atoms) (Figure 1). This metabolic pathway 
requires specific Δ6 and Δ5 desaturases and elongases that are common to both n-6 
and n-3 PUFAs, meaning that these pathways are in competition [10]. LC-PUFA 
Figure 1. 
Synthesis pathways of n-6 and n-3 LC-PUFA and main dietary sources of PUFAs. LA: linoleic acid; LNA: 
linolenic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
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biosynthesis takes place mainly in the liver, especially in both microsomes and 
peroxisomes [11]. However, the brain also possesses the enzymatic equipment and 
can synthesize LC-PUFAs. The main LC-PUFAs for the n-6 and n-3 series, due to 
their role as precursors of bioactive derivatives and due to their level in the brain, 
are arachidonic acid (AA, 20:4 n-6) and docosahexaenoic acid (DHA, 22:6 n-3) 
[12, 13]. Eicosapentaenoic acid (EPA, 20:5 n-3) is also an important n-3 LC-PUFA 
as it is also a precursor of bioactive derivatives despite its low level in the brain 
because of its rapid β-oxidation [14]. Docosapentaenoic acid (DPA, 22:5 n-6) for 
the n-6 family is also relevant because it replaces DHA in the membranes in case 
of dietary n-3 PUFA deficiency. LC-PUFAs are mainly esterified in phospholipids. 
They are also present as free LC-PUFA in very low amount: 1 nmole/g tissue versus 
10 μmoles/g [15].
2.1.2 Dietary origin
The precursors LA and ALA are found mainly in vegetables, oils, and seeds 
(60% of LA in sunflower oil and 10% of ALA in rapeseed oil, for example) (Figure 1) 
[16, 17]. Although human can synthesize LC-PUFAs from these precursors, the 
conversion efficiency is very low (<5%) even in healthy adults [2, 3]. Hence, the main 
part of LC-PUFAs comes from the diet. AA is found in meats (5–10%) and eggs (15%) 
[18, 19] and DHA and EPA are found in fatty fishes (18.7% EPA + DHA in salmon, 
32.9% EPA + DHA in tuna, for example) (Figure 1) [20]. However, lean fishes 
(sole, codfish, etc.) contain also appreciable amounts of DHA and EPA. Therefore, 
LC-PUFAs dietary intakes are crucial to maintain adequate levels of LC-PUFAs in 
membranes. That is why there are dietary recommendations for PUFAs. Dietary 
intakes recommend ~500 mg/day in EPA and DHA (2 portions of fish/week) and 
a ratio LA/ALA close to 4–5 to meet all the needs of the body into DHA and to 
protect against cardiovascular disease risk [21, 22]. Preclinical and clinical studies 
indicate that increasing dietary ALA and reducing LA are beneficial in increasing 
n-3 LC-PUFA bioavailability [23, 24]. Despite these recommendations, dietary n-3 
PUFA intake is insufficient, both for the precursor ALA and the LC-PUFAs DHA and 
EPA. Indeed, in the western diet, there is an imbalance between n-6 and n-3 PUFAs 
leading to an n-3 PUFA consumption 12–20 times lower than n-6 PUFA consump-
tion [10, 25]. This is due to the increased industrialization in the developed nations 
accompanied by changes in dietary habits. It is particularly characterized by an 
increase in LA and AA together with a decrease in ALA and DHA. A high intake of LA 
associated with a low intake of ALA leads to the accumulation of n-6 PUFAs, includ-
ing AA. In case of severe n-3 PUFA deficiency, the expression of desaturases and 
elongases are upregulated in the liver in order to compensate and provide DHA to the 
brain [26, 27]. In addition, under dietary n-3 PUFA deficiency, the half-life of brain 
DHA is increased by twofold as under balanced diet [28]. Dietary lipids, representing 
35–40% of total energy intake, are essentially found (90–95%) in the form of triglyc-
erides (a glycerol backbone with three fatty acids). They are also found in the form of 
phospholipids (in which the 3-position on the glycerol is replaced by a phosphorylated 
alcohol function). There is still a debate concerning the better form to enhance EPA/
DHA bioavailability, krill oil as a source of phospholipids or fish oil as a source of 
triglycerides [29, 30]. More studies have to be performed.
2.2 PUFA content in the brain
The brain contains high levels of PUFAs (25–30%) that are mainly DHA (n-3 
PUFA) (12–14% of total fatty acids) and AA (n-6 PUFA) (8–10% of total fatty 
acids) [12, 31–35]. Most LC-PUFAs accumulate during brain development, especially 
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during the perinatal period: in humans between the beginning of the third trimester 
of gestation and 2 years and in rodents between the 7th and the 21st postnatal day 
[36–38]. These periods correspond to the rapid neuronal maturation, synaptogen-
esis, and gray matter expansion [39, 40]. The brain LC-PUFA content differs in 
brain structures [12, 31, 35, 41, 42], for example, in the adult C57Bl6/J mice, AA 
is higher in hippocampus (10.2%), followed by the prefrontal cortex (9.7%), the 
hypothalamus (8.5%), the cortex (7.7%), the cerebellum (6.5%), and the brain stem 
(5.5%) [12]. DHA is higher in the prefrontal cortex (14.3%) and in the hippocam-
pus (13.7%), followed by cerebellum (12.2%) and cortex (11.9%), hypothalamus 
(10.1%), and brain stem (8.2%) [12]. Then the AA/DHA ratio varies from 0.75 
to 0.85 in the hypothalamus and hippocampus to 0.54 in the cerebellum. These 
variations may be due to different LC-PUFA entry mechanisms into the brain or to 
different incorporation into membranes of cells composing the structure considered. 
These levels are comparable in human: prefrontal cortex contains between 12.3 and 
15.9% of DHA in rats and mice and between 14.1 and 15.9% [12, 35, 43, 44].
2.3 PUFA content in brain cells
Brain cells comprise neurons and glial cells: 70% astrocytes, 10–15% oligoden-
drocytes, and 10–15% microglial cells [45]. Very few studies reported the fatty acid 
composition of the individual cells. Bourre et al. determined the fatty acid composi-
tion in neurons, astrocytes, and oligodendrocytes in 15- or 60-days rats and con-
firmed previous results obtained in 1973 and 1981 [46–49]. We recently described 
the fatty acid composition of microglial cells in 21-days mice [46, 50].
Neurons cannot synthesize LC-PUFAs but can incorporate them in their mem-
branes. They contain 8.2–8.3% DHA and 2.2–2.8% n-3 DPA (22:5 n-3) for n-3 
LC-PUFAs, 10.3–15.1% AA, 2.2% n-6 DPA, and 1.0–2.1% adrenic acid (22: 4 n-6) for 
n-6 LC-PUFAs [46]. They contain 3.1–6.9% LA. Then the ratio n-3/n-6 is 0.46–0.50.
Astrocytes are supportive glial cells that play many roles including synaptic 
transmission and energy metabolite furniture to different neural elements. They 
respond to all forms of central nervous system (CNS) insults through a process 
referred to as reactive astrogliosis. Dysfunctions of astrocytes result in pathologi-
cal changes in the CNS. Astrocytes contain 10.6–12.1% DHA and 0.7–1.3% of n-3 
DPA for n-3 LC-PUFAs and 10.1–10.3% of AA, 2.5–2.7% of n-6 DPA and 2.4–2.7% 
adrenic acid (22:4 n-6) [46]. They contain few PUFA precursors: only 1.2–1.4% of 
LA and no ALA. The ratio n-3/n-6 is 0.72–0.76.
Oligodendrocytes provide a supporting role for neurons and are involved in the 
formation of myelin sheaths of nerve cell axons. They are highly dynamic and can 
respond to environmental influences and neuronal activity. They can also regener-
ate myelin spontaneously after CNS injury. Any disturbances in their functioning 
are associated with major diseases of the nervous system. They contain mainly 5.1% 
DHA for n-3 LC-PUFAs and 9.3% AA and 3.5% n-6 DPA for n-6 LC-PUFAs [46]. 
They contain not as much as LA: only 2.7%. The ratio n-3/n-6 is 0.33.
Microglial cells are the innate immune cells of the brain. They play a major role in 
synaptogenesis, synapse structure and function, and neuroinflammation. They perpet-
ually scan and control their environment and once activated, they deliver pro-inflam-
matory and pro-regeneration responses. Their fatty acid composition differs from that 
of the other brain cells. In all these cells, DHA is the main fatty acid. Microglial cells are 
characterized by few DHA (<1%) and n-3 DPA (0.1%) but high content of EPA (3.7%) 
[50]. They contain few AA (1.6%). They contain PUFA precursors: 8.0% LA and 1.3% 
ALA. The ratio n-3/n-6 is 0.42. This microglial fatty acid composition also differs from 
the whole brain hippocampus that contains higher DHA than EPA [51]. Then, it seems 
that EPA metabolism is different in microglial cells than in other brain cells and the 
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whole brain structure. It is not highly β-oxidized as in the whole brain [52]. More studies 
have to be performed to elucidate the role of EPA in microglial cells.
2.4 Nutrition as a major factor of variation of brain and brain cell PUFA content
Nutrition is an environmental factor to which individuals are continuously 
exposed throughout life. And it is an environmental factor that changed a lot these 
last decades. Indeed, there was a dramatic reduction in the dietary supply of n-3 
PUFAs in western societies associated with a drastic increase in the n-6 PUFAs, 
leading to an imbalanced n-6/n-3 PUFA ratio estimated at 12–20 in developed 
countries instead of five recommended [10].
This is particularly important considering that brain fatty acid composition var-
ies with the fatty acids of the dietary supply [53]. Indeed, PUFA content is strongly 
impacted by the dietary PUFAs in all brain structures [12, 54]. A diet deficient in 
n-3 PUFA precursor during development and/or adulthood decreases brain DHA 
in all brain structures; the prefrontal cortex and the hippocampus that contain the 
highest DHA content are the most sensitive whereas the hypothalamus that contains 
the lowest DHA, is the least sensitive [12, 31, 55–58]. These differences may be 
attributed to the evolution of brain performance [59, 60]. In such case of n-3 PUFA 
deficiency, changes in metabolism occur: the half-life of DHA increases in the brain 
to reduce its loss [61] and the activity of DHA synthesis enzymes (Δ6 destaurase 
and elongase) is increased in the liver [26, 62, 63]. In contrast to the deficiency, the 
supplementation in n-3 LC-PUFAs increases brain DHA [64–67]. DHA supple-
mentation is more efficient than ALA supplementation to increase brain DHA [68, 
69]. A DHA supplementation is also efficient to reverse brain DHA decrease due to 
an n-3 PUFA deficiency or to aging [33, 70–72]. Also, genetic models of n-3 PUFA 
enrichment such as Fat-1 mice possess higher brain DHA content [12, 73–77].
Brain cells are also impacted by dietary PUFA supply. An n-3 PUFA precursor-
deficient diet decreases DHA in neurons (4.6% versus 8.2% in 15-day old ani-
mals and 2.4 versus 8.3% in 60-day old animals), astrocytes (3.1 versus 10.6% in 
15-day old animals and 5.7 versus 12.1% in 60-day old animals), and oligodendro-
cytes (0.1% versus 5.1% in 60-day old animals) [46]. These changes decrease the 
n-3/n-6 ratio (0.24 versus 0.46–0.50 in neurons, 0.12–0.25 versus 0.72–0.76 in astro-
cytes and 0.02 versus 0.33 in oligodendrocytes). Interestingly, we recently find that 
a maternal n-3 PUFA precursor deficiency increases n-6 DPA but does not affect 
DHA level in microglial cells in 21-day-old animals, suggesting that these cells are 
protected from n-3 PUFA deficiency [50]. However, we also report that a maternal 
n-3 LC-PUFA supplementation increases DHA levels and decreases n-6 DPA levels 
in these animals, confirming results previously obtained in glial cells [78, 79].
All these results suggest that brain DHA levels are highly variables, depending 
on the brain structures or brain cells considered and on the dietary fatty acid intake. 
This may have consequences on inflammatory processes since n-3 LC-PUFAs have 
immunomodulatory properties [80].
3. Bioactive PUFA derivatives
3.1 Bioactive PUFA derivative metabolism
3.1.1 PUFA derivative synthesis pathways
Some of the immunomodulatory properties of LC-PUFAs are attributed to the 
synthesis of bioactive lipid mediators. Different lipid mediators are synthesized: those 
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involved in the regulation of inflammation such as the eicosanoids (prostaglandins, 
leukotrienes, and thromboxanes) and those implicated in the resolution of inflam-
mation called specialized pro-resolving mediators (SPMs, resolvins, protectins, and 
maresins) (Figure 2). Among the eicosanoids, those synthesized from n-3 PUFAs are 
less potent inflammatory than those synthesized from n-6 PUFAs [81] highlighting 
the interest to increase n-3 PUFA and decrease n-6 PUFA contents in the membranes. 
Then, when co-present, EPA-derived eicosanoids antagonize those synthesized 
from AA. The main EPA-derived mediators include 3-series prostaglandin (PG), 
5-series leukotriene (LT), and 3-series thromboxane (TX), reported to be nonac-
tive (Figure 2). DHA is also converted into 3-series PG (Figure 2). In addition, 
eicosanoids synthesized from AA and EPA act in competition as they share the same 
G-protein-coupled receptors. Moreover, EPA is a competitive inhibitor to AA. Indeed, 
it reduces the production of AA by inhibiting the activity of Δ5 desaturase convert-
ing dihomo-gamma-linolenic acid (dGLA) into AA [81]. EPA also reduces in vitro 
the production of AA-derived eicosanoids by inhibiting the activity of cyclooxy-
genase-2 (COX-2) and 5-lipoxygenase (5-LOX) generating the eicosanoids [82–84]. 
Eicosanoids are synthesized first in the time course of the inflammatory response. 
Then, there is a switch in the bioactive lipid mediator class: SPMs derived from n-3 
LC-PUFAs are synthesized to induce the resolution of inflammation and a return to 
homeostasis (Figure 3). DHA is the precursor of D-series resolvins, neuroprotectin 
D1 (NPD1), and Maresin 1–2 (Mar1–2) and EPA is the precursor of E-series resolvins, 
all these derivatives underlying most of the beneficial effects attributed to their pre-
cursors [1, 85–87]. These derivatives have both anti-inflammatory and pro-resolution 
properties without immune suppression [6, 8, 88, 89]. SPMs actively orchestrate and 
finely tune the inflammatory response. They decrease pro-inflammatory cytokines 
and increase anti-inflammatory cytokines and accelerate the phagocytosis of cellular 
debris and dead cells without immune suppression. They are synthesized via COX-2, 
LOX, and cytochrome P450 monooxygenases (CYP450) once they have been released 
from membrane phospholipids by phospholipase A2 in response to stimulation. These 
Figure 2. 
Main bioactive lipid mediators synthesized from n-3 PUFAs. DHA: docosahexaenoic acid; EPA: 
eicosapentaenoic acid; LNA: linolenic acid; LT: leukotriene; NPD1: neuroprotection D1; PG: prostaglandin; 
SPMs: specialized pro-resolving mediators; Tx: thromboxane.
7Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
enzymes are expressed in the brain [90–92]. In response to lipopolysaccharide (LPS) 
that induces inflammation, COX-2 is rapidly expressed in the hippocampus [69, 93] 
and inhibition of COX-2 delays resolution of acute inflammation [94]. 15-LOX and 
5-LOX are the most abundant LOX in the brain [90]. 15-LOX has a dual role since it is 
involved in neurodegeneration and neurotoxicity due to the increased stress it gener-
ates [95–97] and is also involved in neuroprotection [98]. 15-LOX deletion or inhibi-
tion decreases SPM production in the brain and cognitive alterations [90]. CYP450 
generates n-6 derived epoxides that are anti-inflammatory [99–102]. These enzymes 
are also expressed in microglia, astrocytes, oligodendrocytes, and neurons [103–106].
3.1.2 Bioactive lipid mediators
DHA is converted into monohydroxy DHA (17-HDHA) by acetylated COX-2, 
CYP450, and 15-LOX [107, 108] and then into RvD1 by 5-LOX [109, 110]. RvD1 
and its precursors have mostly been described at the periphery but have also been 
detected in the brain. RvD1 was measured in mouse brain following cerebral 
ischemia. Its level is increased following a DHA intravenous injection [111] and 
modulated during inflammation: it decreases at the beginning and then increases 
during the resolution phase [112]. RvD1 acts through the regulation of micro-
RNAs (miRNAs) that modulate the expression of target genes such as inflamma-
tory genes [113–117]. DHA can also be converted into di-hydroxy-DHA termed 
protectin D1 (PD1) or neuroprotectin D1 (NPD1) when produced in the CNS by 
5- and 15-LOX [118–121]. NPD1 was measured in hippocampus. Its level greatly 
is increased following brain ischemia or acute central LPS injection [70, 122] and 
decreased in the hippocampus of Alzheimer’s disease patients [123]. NPD1 acts 
through NFkB and then decreases pro-inflammatory gene expression [122, 124, 
125]. At last, DHA can also be converted into 14-HDHA and then in Mar1–2 by 
12/15-LOX [107, 108, 126]. Mar1 and its precursor 14-HDHA have recently been 
identified in the hippocampus of mice [70]. Its level is decreased in post-mortem 
Alzheimer’s disease patients contributing to the progression of this pathology 
[127]. Mar1 promotes the resolution of inflammation, reducing pro-inflammatory 
cytokines, silencing pro-inflammatory signaling cascades, and enhancing M2 
repair macrophage phenotype after cerebral ischemia or spinal cord injury 
[128–130] (Figure 3).
EPA is converted into resolvins E1, E2, and E3 by acetylated COX-2 or CYP450 
via 18R-HEPE by 5- or 15-LOX [107, 131, 132]. RvE1 and its precursor have been 
detected in hippocampus [70, 133, 134]. RvE1 inhibits NFκB signaling pathway and 
then decreases LPS-induced proinflammatory cytokines (TNF-α, IL-6, and IL-1β) 
gene expression in microglial cells [117].
3.1.3 SPM receptors
SPMs act through specific receptors, some but not all of them have recently been 
identified. RvD1 acts through lipoxin A4 receptor/formyl peptide receptor 2 (ALX/
Fpr2) in rodents and G protein coupling receptor 32 (GPR32) in human [109] at 
picomolar range but induces biological effects at nanomolar range [110, 135]. RvE1 
directly binds to its receptor G protein coupling receptor ChemR23 or chemokine 
like receptor 1 (CMKLR1) [131]. It is also a partial agonist of a leukotriene B4 
receptor (BLT1) [136]. In the CNS, ALX/Fpr2 has been identified in the brainstem, 
spinal cord, hypothalamus, cortex, hippocampus, cerebellum, and striatum [137] 
and ChemR23 in the prefrontal cortex, hippocampus, and brainstem [138]. At the 
cellular levels, these two receptors have been detected in microglial cells [117, 139], 
neurons [137, 140] and astrocytes [96, 113] (Figure 3).
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Other receptors have not been identified yet (Mar1 receptor) [127] or identified 
only at the periphery in macrophages but not in microglia (NPD1 receptor) [141].
In the next sections, we will focus on the role of these SPMs to better understand 
the beneficial effects of the n-3 PUFAs.
3.2 Role of bioactive lipid derivatives in neuroinflammation
SPMs have multiple biological roles, focusing to the return to homeostasis. In 
human serum, DHA- and EPA-derivatives represent 30.7 and 25.9% of the identi-
fied SPMs, respectively [142, 143]. The most SPMs studied are RvD1 and RvE1 
because they have powerful anti-inflammatory and pro-resolution properties. We 
will then detail the biological roles for these two bioactive mediators.
3.2.1 Biological role of RvD1 and RvE1 in humans
The effect of RvD1 was mainly studied in patients suffering from Alzheimer’s 
disease. Interestingly, RvD1 levels in cerebrospinal fluid are positively correlated 
with the enhancement of cognitive functions of patients with dementia [96]. 
Moreover, it was suggested in vitro in macrophages isolated from Alzheimer’s 
patients that RvD1 may be involved in Aβ phagocytosis [144, 145]. Then the 
decrease in RvD1 levels in Alzheimer’s patient brain could contribute to the dis-
ease development. To our knowledge, the effect of RvE1 in humans was shown 
at the periphery (on patients undergoing hepatobiliary resection, pulmonary 
Figure 3. 
Specialized pro-resolving mediator (SPM) synthesis. 14-HDHA: 14-hydroxy-docosahexaenoic acid; 17-HDHA: 
17-hydroxy-docosahexaenoic acid; 18-HEPE: 18-hydroxy-eicosapentaenoic acid; ALX/Fpr2: N-formyl 
peptide receptor 2; BLT1: leukotriene B4 receptor; COX-2: cyclooxygenases; DHA: docosahexaenoic acid; EPA: 
eicosapentaenoic acid; GPR32/37: G protein-coupled receptor 32/37; LC-PUFAs: long chain polyunsaturated 
fatty acids; LOX: lipoxygenases.
9Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
inflammation, and bone disease periodontitis) [146–148] but not at the brain level 
on patients suffering from neurodegenerative diseases.
3.2.2 Biological roles of RvD1 and RvE1 in rodents
RvD1 and RvE1 are active in reducing the pro-inflammatory status in the 
CNS. Indeed, the precursors of RvD1, 17R-HDHA, and 17S-HDHA decrease the 
production of pro-inflammatory cytokines TNF-α in the spinal cord and IL-1β and 
TNF-α in the hippocampus [70, 149]. Moreover, RvD1 is able to induce the polariza-
tion of macrophages and microglia toward an M2 phagocytic phenotype [150–152]. 
In addition, RvD1 reduces neuroinflammation via miRNA in a model of remote 
damage [113]. RvE1 also modulates inflammation by reducing the proinflammatory 
cytokines IL-1β and IL-6 in the prefrontal cortex and decreases the measures of 
Aβ pathology in a murine model of Alzheimer’s disease [153]. Furthermore, RvE1 
treatment decreases brain microglial activation following traumatic brain injury 
or peripheral brain injury, decreasing the proportion of activated microglia at the 
expense of ramified microglia [154, 155].
RvD1 is also involved in the prevention of cognitive deficits. In a systemic 
inflammation model, cognitive decline is prevented by an intraperitoneal (ip) injec-
tion of the precursor of RvD1, 17R-HDHA, and is associated with the restoration of 
transmission and synaptic plasticity and to the prevention of astrogliosis [154, 156]. 
Moreover, in a model of traumatic brain injury, cognitive deficits are also prevented 
by an ip chronic administration of 17R-HDHA [154]. Of note, Fat-1 mice that 
have more brain n-3 LC-PUFAs have higher hippocampus RvD1 that is associated 
with less cognitive deficits, a better neuronal survival, a decrease in astrocyte and 
microglial activation and a reduction in pro-inflammatory status following brain 
ischemia [77, 157]. Inversely, an inhibition of 15-LOX associated with a decrease in 
RvD1 induces alterations in synaptic plasticity and working memory [90].
Additionally, RvD and E are also associated with the prevention of depressive-
like behaviors [158]. An intracerebroventricular (icv) injection of RvD1, D2, E1, 
E2, or E3 significantly decreases LPS-induced depressive-like behaviors [159–161]. 
Moreover, an intrathecal injection of 17R-HDHA prevents the occurrence of 
depressive-like behaviors and is associated with the decrease of pain perception and 
a restoration of dopamine and glutamate levels in the brain [149, 162]. RvD1 and D2 
have also positive effects in chronic mild stress-induced depression and in post-
myocardial infarct depression [163, 164].
3.2.3 Biological roles of RvD1 and RvE1 in in vitro brain cell models
The effects of RvD1 were tested on different brain cells. In microglial cells, 
RvD1 potentiates the activation of the anti-inflammatory M2 phenotype of 
microglia, enhancing the effect of the anti-inflammatory cytokine IL-4, Arg1, 
and Ym1 expression and decreasing CD11b expression [152, 155, 165]. Moreover, 
we showed that RvD1 decreases LPS-induced proinflammatory cytokine (TNF-
α, IL-6 and IL-1β) gene expression in microglial BV2 cells via the modulation 
of miRNAs [117]. RvD2 inhibits LPS-induced activation of toll-like receptor 4 
(TLR4, the receptor of LPS) and its downstream signaling pathway NFκB [166]. 
RvE1 plays also a direct role in microglial cells by inhibiting microglial activation 
and pro-inflammatory cytokine release [117, 155]. These results suggest the pro-
resolution activity of RvD1 and RvE1 in microglia. In astrocytes, RvD1 decreases 
TNF-α release induced by LPS injection [149]. In neurons from spinal nods, RvD1 
increases neurite outgrowth [167].
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All these studies point out the central role of n-3 LC-PUFA and their bioactive 
mediators in the regulation of inflammation in the brain, especially through their 
effect on microglia.
3.3 Nutrition as a factor of variation of SPM levels
The level of these lipid derivatives is modulated by the diet. Indeed, we recently 
show that a dietary n-3 LC-PUFA supplementation induces an n-3 LC-PUFA 
enrichment in the hippocampus associated with an increase in n-3 PUFA-derived 
SPMs and a decrease in n-6 PUFA-derived SPMs [69]. Our results confirm previous 
ones reporting that oral administration of EPA and DHA results in the generation of 
EPA-and DHA-derived mediators in the cortex of aged rats [168] and in the down-
regulation of the production of n-6 PUFA-derived mediators [169, 170]. The cellular 
origin of these bioactive lipid derivatives is still unknown. As described in the para-
graph above, we know that dietary PUFA supplementation affects PUFA composi-
tion in brain cells that potentially could impact brain cell PUFA lipid derivatives. In 
response to LPS, n-3 LC-PUFA-supplemented mice display an anti-inflammatory 
SPM profile whereas n-3 LC-PUFA-deficient mice exhibit a pro-inflammatory SPM 
profile [69]. These results corroborate previous ones in vivo [171–176] and in vitro in 
macrophages [177, 178] and microglia [179–181].
The level of SPMs is also dependent on the regulation of their biosynthesis 
enzymes. 15-LOX mRNA expression increases in n-3 LC-PUFA supplemented group 
and decreases in n-3 LC-PUFA deficient diet [27, 69, 182]. 15-LOX has beneficial 
properties such as neuroprotective properties via PPAR-γ activation [98] and 
preservation of cognitive performance through RvD1 formation [90]. 15-LOX has 
also detrimental effects as it is implicated in neurodegeneration and neurotoxicity 
through increase of oxidative stress [95–97].
Changes in SPM level and composition induced by the diet can have a great 
influence on the pro- and anti-inflammatory status of hippocampus and brain cells 
and reinforce the recommendation of n-3 PUFA-rich diet.
4. Conclusion
These data highlight that n-3 LC-PUFA and their bioactive lipid derivatives 
are important regulators of neuroinflammation. SPMs are promising therapeutic 
compounds: they are of natural origin and act in physiologic dose ranges (nanomo-
lar) as compared to EPA and DHA that act at micromolar ranges, and this confers 
the main advantage to use SPMs. Both brain n-3 LC-PUFA and SPMs are modulated 
by the diet in the brain and in brain cells confirming the notable role of nutrition 
in the regulation of inflammation. Alteration in dietary n-3 PUFAs should have 
dramatic consequences in brain and brain cell PUFA metabolism and finally in the 
response to neuroinflammation. The use of SPMs to treat neuroinflammation is still 
in emergence since some data are missing such as the affinity and function of SPM 
receptors. This field has to be completed. The instability of SPMs may be bypassed 
by the use of SPM analogues or by their encapsulation. The clinical form and the 
way of administration should also be defined.
Acknowledgements
Corinne Joffre was sponsored by the Fondation de France and the Fondation 
pour la Recherche Médicale.
11




1 INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, Bordeaux, France
2 Université de Bordeaux 2, Bordeaux Cedex, France
*Address all correspondence to: corinne.joffre@inra.fr
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
12
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
[1] Bazinet RP, Layé S. Polyunsaturated 
fatty acids and their metabolites in brain 
function and disease. Nature Reviews. 
Neuroscience. Dec. 2014;15(12):771-785
[2] Kidd PM. Omega-3 DHA and EPA for 
cognition, behavior, and mood: Clinical 
findings and structural-functional 
synergies with cell membrane 
phospholipids. Alternative Medicine 
Review. Sep. 2007;12(3):207-227
[3] Plourde M, Cunnane SC. Extremely 
limited synthesis of long chain 
polyunsaturates in adults: Implications 
for their dietary essentiality and use 
as supplements. Applied Physiology, 
Nutrition, and Metabolism. Aug. 
2007;32(4):619-634
[4] Dantzer R, O’Connor JC, Freund 
GG, Johnson RW, Kelley KW. From 
inflammation to sickness and 
depression: When the immune system 
subjugates the brain. Nature Reviews. 
Neuroscience. Jan. 2008;9(1):46-56
[5] Calder PC. Marine omega-3 fatty 
acids and inflammatory processes: 
Effects, mechanisms and clinical 
relevance. Biochimica et Biophysica 
Acta. Apr. 2015;1851(4):469-484
[6] Serhan CN, Clish CB, Brannon J, 
Colgan SP, Chiang N, Gronert K. Novel 
functional sets of lipid-derived 
mediators with antiinflammatory 
actions generated from omega-3 
fatty acids via cyclooxygenase 
2-nonsteroidal antiinflammatory 
drugs and transcellular processing. The 
Journal of Experimental Medicine. Oct. 
2000;192(8):1197-1204
[7] Serhan CN. The resolution of 
inflammation: The devil in the flask and 
in the details. The FASEB Journal. May 
2011;25(5):1441-1448
[8] Serhan CN. Pro-resolving 
lipid mediators are leads for 
resolution physiology. Nature. Jun. 
2014;510(7503):92-101
[9] Spite M, Serhan CN. Novel lipid 
mediators promote resolution of acute 
inflammation: Impact of aspirin and 
statins. Circulation Research. Nov. 
2010;107(10):1170-1184
[10] Simopoulos AP. Evolutionary 
aspects of diet: The omega-6/omega-3 
ratio and the brain. Molecular 
Neurobiology. Oct. 2011;44(2):203-215
[11] Sprecher H. Metabolism of highly 
unsaturated n-3 and n-6 fatty acids. 
Biochimica et Biophysica Acta. Jul. 
2000;1486(2-3):219-231
[12] Joffre C et al. Modulation of brain 
PUFA content in different experimental 
models of mice. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
2016;114:1-10
[13] Kitajka K et al. Effects of dietary 
omega-3 polyunsaturated fatty acids 
on brain gene expression. Proceedings 
of the National Academy of Sciences 
of the United States of America. Jul. 
2004;101(30):10931-10936
[14] Chen CT, Bazinet RP. beta-oxidation 
and rapid metabolism, but not uptake 
regulate brain eicosapentaenoic acid 
levels. Prostaglandins, Leukotrienes, 
and Essential Fatty Acids. Jan. 
2015;92:33-40
[15] Green JT, Liu Z, Bazinet RP. Brain 
phospholipid arachidonic acid half-lives 
are not altered following 15 weeks of 
N-3 polyunsaturated fatty acid adequate 
or deprived diet. Journal of Lipid 
Research. Mar. 2010;51(3):535-543
[16] Orsavova J, Misurcova L, 
Ambrozova JV, Vicha R, Mlcek J. Fatty 
acids composition of vegetable oils and 
its contribution to dietary energy intake 
and dependence of cardiovascular 
References
13
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
mortality on dietary intake of fatty 
acids. International Journal of Molecular 
Sciences. Jun. 2015;16(6):12871-12890
[17] Lewinska A, Zebrowski J, Duda M, 
Gorka A, Wnuk M. Fatty acid profile 
and biological activities of linseed 
and rapeseed oils. Molecules. Dec. 
2015;20(12):22872-22880
[18] Meyer BJ, Mann NJ, Lewis JL, 
Milligan GC, Sinclair AJ, Howe PRC.  
Dietary intakes and food sources 
of omega-6 and omega-3 
polyunsaturated fatty acids. Lipids. Apr. 
2003;38(4):391-398
[19] Taber L, Chiu CH, Whelan J.  
Assessment of the arachidonic acid 
content in foods commonly consumed 
in the American diet. Lipids. Dec. 
1998;33(12):1151-1157
[20] Strobel C, Jahreis G, Kuhnt K.  
Survey of n-3 and n-6 polyunsaturated 
fatty acids in fish and fish products. 
Lipids in Health and Disease. Oct. 
2012;11:144
[21] Burdge G. Alpha-linolenic acid 
metabolism in men and women: 
Nutritional and biological implications. 
Current Opinion in Clinical 
Nutrition and Metabolic Care. Mar. 
2004;7(2):137-144
[22] Lucas M, Asselin G, Mérette C, 
Poulin M-J, Dodin S. Validation of an 
FFQ for evaluation of EPA and DHA 
intake. Public Health Nutrition. Oct. 
2009;12(10):1783-1790
[23] Blanchard H, Pédrono F, Boulier-
Monthéan N, Catheline D, Rioux V, 
Legrand P. Comparative effects of well-
balanced diets enriched in α-linolenic or 
linoleic acids on LC-PUFA metabolism 
in rat tissues. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
May 2013;88(5):383-389
[24] Taha AY et al. Dietary omega-6 fatty 
acid lowering increases bioavailability 
of omega-3 polyunsaturated fatty 
acids in human plasma lipid pools. 
Prostaglandins, Leukotrienes, 
and Essential Fatty Acids. May 
2014;90(5):151-157
[25] Simopoulos AP. The importance 
of the ratio of omega-6/omega-3 
essential fatty acids. Biomedicine 
& Pharmacotherapy. Oct. 
2002;56(8):365-379
[26] Igarashi M, Ma K, Chang L, Bell JM, 
Rapoport SI. Dietary n-3 PUFA 
deprivation for 15 weeks upregulates 
elongase and desaturase expression in 
rat liver but not brain. Journal of Lipid 
Research. Nov. 2007;48(11):2463-2470
[27] Rao JS, Ertley RN, DeMar JC,  
Rapoport SI, Bazinet RP, Lee 
H-J. Dietary n-3 PUFA deprivation 
alters expression of enzymes of the 
arachidonic and docosahexaenoic acid 
cascades in rat frontal cortex. Molecular 
Psychiatry. Feb. 2007;12(2):151-157
[28] DeMar JC Jr, Ma K, Bell JM,  
Rapoport SI. Half-lives of 
docosahexaenoic acid in rat brain 
phospholipids are prolonged by 15 
weeks of nutritional deprivation 
of n-3 polyunsaturated fatty acids. 
Journal of Neurochemistry. Dec. 
2004;91(5):1125-1137
[29] Salem N, Kuratko CN. A 
reexamination of krill oil bioavailability 
studies. Lipids in Health and Disease. 
Aug. 2014;13:137
[30] Yurko-Mauro K, Kralovec J, Bailey-
Hall E, Smeberg V, Stark JG, Salem 
N. Similar eicosapentaenoic acid and 
docosahexaenoic acid plasma levels 
achieved with fish oil or krill oil in a 
randomized double-blind four-week 
bioavailability study. Lipids in Health 
and Disease. Sep. 2015;14:99
[31] Carrie I, Clement M, de Javel D,  
Frances H, Bourre JM. Specific 
phospholipid fatty acid composition 
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
14
of brain regions in mice. Effects of n-3 
polyunsaturated fatty acid deficiency 
and phospholipid supplementation. 
Journal of Lipid Research. Mar. 
2000;41(3):465-472
[32] Chung WL, Chen JJ, Su HM. Fish 
oil supplementation of control and 
(n-3) fatty acid-deficient male rats 
enhances reference and working 
memory performance and increases 
brain regional docosahexaenoic acid 
levels. The Journal of Nutrition. Jun. 
2008;138(6):1165-1171
[33] Little SJ, Lynch MA, Manku M, 
Nicolaou A. Docosahexaenoic acid-
induced changes in phospholipids 
in cortex of young and aged rats: A 
lipidomic analysis. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
Oct. 2007;77(3-4):155-162
[34] McNamara RK, Carlson SE. Role 
of omega-3 fatty acids in brain 
development and function: Potential 
implications for the pathogenesis 
and prevention of psychopathology. 
Prostaglandins, Leukotrienes, 
and Essential Fatty Acids. Oct. 
2006;75(4-5):329-349
[35] Xiao Y, Huang Y, Chen 
ZY. Distribution, depletion and 
recovery of docosahexaenoic acid 
are region-specific in rat brain. The 
British Journal of Nutrition. Oct. 
2005;94(4):544-550
[36] Clandinin MT, Chappell JE, 
Leong S, Heim T, Swyer PR, Chance 
GW. Extrauterine fatty acid accretion 
in infant brain: Implications for fatty 
acid requirements. Early Human 
Development. Jun. 1980;4(2):131-138
[37] Clandinin MT, Chappell JE, Leong 
S, Heim T, Swyer PR, Chance GW.  
Intrauterine fatty acid accretion rates 
in human brain: Implications for fatty 
acid requirements. Early Human 
Development. Jun. 1980;4(2):121-129
[38] Green P, Glozman S, Kamensky B,  
Yavin E. Developmental changes 
in rat brain membrane lipids and 
fatty acids. The preferential prenatal 
accumulation of docosahexaenoic 
acid. Journal of Lipid Research. May 
1999;40(5):960-966
[39] Giedd JN et al. Brain development 
during childhood and adolescence: 
A longitudinal MRI study. Nature 
Neuroscience. Oct. 1999;2(10):861-863
[40] Morgane PJ et al. Prenatal 
malnutrition and development of the 
brain. Neuroscience and Biobehavioral 
Reviews. Spring 1993;17(1):91-128
[41] Delion S, Chalon S, Hérault J, 
Guilloteau D, Besnard JC, Durand G.  
Chronic dietary alpha-linolenic acid 
deficiency alters dopaminergic and 
serotoninergic neurotransmission in 
rats. The Journal of Nutrition. Dec. 
1994;124(12):2466-2476
[42] McNamara RK, Able J, Jandacek R,  
Rider T, Tso P. Inbred C57BL/6J 
and DBA/2J mouse strains exhibit 
constitutive differences in regional 
brain fatty acid composition. Lipids. 
Jan. 2009;44(1):1-8
[43] Moriguchi T, Loewke J, Garrison M,  
Catalan JN, Salem N Jr. Reversal of 
docosahexaenoic acid deficiency in 
the rat brain, retina, liver, and serum. 
Journal of Lipid Research. Mar. 
2001;42(3):419-427
[44] Hamazaki K, Maekawa M, Toyota T, 
Dean B, Hamazaki T, Yoshikawa T. Fatty 
acid composition of the postmortem 
prefrontal cortex of patients with 
schizophrenia, bipolar disorder, and 
major depressive disorder. Psychiatry 
Research. Jun. 2015;227(2-3):353-359
[45] Renaud J, Therien HM, Plouffe M, 
Martinoli MG. Neuroinflammation: 
Dr Jekyll or Mr Hyde? Medical Science 
(Paris). Nov. 2015;31(11):979-988
15
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
[46] Bourre JM, Pascal G, Durand G, 
Masson M, Dumont O, Piciotti M.  
Alterations in the fatty acid 
composition of rat brain cells (neurons, 
astrocytes, and oligodendrocytes) 
and of subcellular fractions (myelin 
and synaptosomes) induced by 
a diet devoid of n-3 fatty acids. 
Journal of Neurochemistry. Aug. 
1984;43(2):342-348
[47] Cohen SR, Bernsohn J.  
Incorporation of 1-14C labeled fatty 
acids into isolated neuronal soma, 
astroglia and oligodendroglia from calf 
brain. Brain Research;60(2):521-525
[48] Morand O, Masson M, Baumann N, 
Bourre JM. Exogenous [1-14C]lignoceric 
acid uptake by neurons, astrocytes and 
myelin, as compared to incorporation 
of [1-14C]palmitic and stearic acids. 
Neurochemistry International. 
1981;3(5):329-334
[49] Morand O et al. Alteration in 
fatty acid composition of neurons, 
astrocytes, oligodendrocytes, myelin 
and synaptosomes in intrauterine 
malnutrition in rat. Annals of Nutrition 
& Metabolism. 1982;26(2):111-120
[50] Rey C et al. Maternal n-3 
polyunsaturated fatty acid dietary 
supply modulates microglia lipid 
content in the offspring. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
2018;133:1-7
[51] Madore C et al. Nutritional n-3 
PUFAs deficiency during perinatal 
periods alters brain innate immune 
system and neuronal plasticity-
associated genes. Brain, Behavior, and 
Immunity. Oct. 2014;41:22-31
[52] Chen CT, Liu Z, Ouellet M, Calon 
F, Bazinet RP. Rapid beta-oxidation 
of eicosapentaenoic acid in mouse 
brain: An in situ study. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
Feb. 2009;80(2-3):157-163
[53] Calder PC. Immunomodulation by 
omega-3 fatty acids. Prostaglandins, 
Leukotrienes, and Essential Fatty Acids. 
Dec. 2007;77(5-6):327-335
[54] Alashmali SM, Hopperton KE,  
Bazinet RP. Lowering dietary 
n-6 polyunsaturated fatty acids: 
Interaction with brain arachidonic and 
docosahexaenoic acids. Current Opinion 
in Lipidology. Feb. 2016;27(1):54-66
[55] Connor WE, Neuringer M, Lin DS.  
Dietary effects on brain fatty acid 
composition: The reversibility of n-3 
fatty acid deficiency and turnover of 
docosahexaenoic acid in the brain, 
erythrocytes, and plasma of rhesus 
monkeys. Journal of Lipid Research. 
Feb. 1990;31(2):237-247
[56] Larrieu T, Madore C, Joffre C, Layé 
S. Nutritional n-3 polyunsaturated fatty 
acids deficiency alters cannabinoid 
receptor signaling pathway in the brain 
and associated anxiety-like behavior 
in mice. Journal of Physiology and 
Biochemistry. Dec. 2012;68(4):671-681
[57] Delpech J-C et al. Dietary 
n-3 PUFAs deficiency increases 
vulnerability to inflammation-
induced spatial memory impairment. 
Neuropsychopharmacology. Nov. 
2015;40(12):2774-2787
[58] Manduca A et al. Amplification 
of mGlu5-endocannabinoid signaling 
rescues behavioral and synaptic 
deficits in a mouse model of adolescent 
and adult dietary polyunsaturated 
fatty acid imbalance. Journal of 
Neuroscience;37(29):6851-6868
[59] Broadhurst CL, Wang Y, Crawford 
MA, Cunnane SC, Parkington JE, 
Schmidt WF. Brain-specific lipids from 
marine, lacustrine, or terrestrial food 
resources: Potential impact on early 
African Homo sapiens. Comparative 
Biochemistry and Physiology. Part B, 
Biochemistry & Molecular Biology. Apr. 
2002;131(4):653-673
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
16
[60] Crawford MA et al. Evidence for 
the unique function of docosahexaenoic 
acid during the evolution of the 
modern hominid brain. Lipids. 
1999;34(Suppl):S39-S47
[61] Rapoport SI, Rao JS, Igarashi M.  
Brain metabolism of nutritionally 
essential polyunsaturated fatty acids 
depends on both the diet and the 
liver. Prostaglandins, Leukotrienes, 
and Essential Fatty Acids. Nov. 
2007;77(5-6):251-261
[62] Cho HP, Nakamura MT, 
Clarke SD. Cloning, expression, 
and nutritional regulation of the 
mammalian Delta-6 desaturase. The 
Journal of Biological Chemistry. Jan. 
1999;274(1):471-477
[63] Wang Y, Botolin D, Christian B, 
Busik J, Xu J, Jump DB. Tissue-specific, 
nutritional, and developmental 
regulation of rat fatty acid elongases. 
Journal of Lipid Research. Apr. 
2005;46(4):706-715
[64] de Theije CG et al. Dietary long 
chain n-3 polyunsaturated fatty acids 
prevent impaired social behaviour and 
normalize brain dopamine levels in food 
allergic mice. Neuropharmacology. Mar. 
2015;90:15-22
[65] Hiratsuka S, Koizumi K, Ooba 
T, Yokogoshi H. Effects of dietary 
docosahexaenoic acid connecting 
phospholipids on the learning ability 
and fatty acid composition of the 
brain. Journal of Nutritional Science 
and Vitaminology (Tokyo). Aug. 
2009;55(4):374-380
[66] Kitson AP et al. Effect of dietary 
docosahexaenoic acid (DHA) in 
phospholipids or triglycerides on 
brain DHA uptake and accretion. The 
Journal of Nutritional Biochemistry. Jul. 
2016;33:91-102
[67] Skorve J et al. Fish oil and krill oil 
differentially modify the liver and brain 
lipidome when fed to mice. Lipids in 
Health and Disease. Aug. 2015;14:88
[68] Lacombe RJS, Giuliano V, Colombo 
SM, Arts MT, Bazinet RP. Compound-
specific isotope analysis resolves the 
dietary origin of docosahexaenoic acid 
in the mouse brain. Journal of Lipid 
Research. Oct. 2017;58(10):2071-2081
[69] Rey C et al. Dietary n-3 long chain 
PUFA supplementation promotes a pro-
resolving oxylipin profile in the brain. 
Brain, Behavior, and Immunity. Feb. 
2019;76:17-27
[70] Orr SK et al. Unesterified 
docosahexaenoic acid is protective 
in neuroinflammation. Journal 
of Neurochemistry. Nov. 
2013;127(3):378-393
[71] Bascoul-Colombo C, Guschina 
IA, Maskrey BH, Good M, O’Donnell 
VB, Harwood JL. Dietary DHA 
supplementation causes selective 
changes in phospholipids from different 
brain regions in both wild type mice and 
the Tg2576 mouse model of Alzheimer’s 
disease. Biochimica et Biophysica Acta. 
Jun. 2016;1861(6):524-537
[72] Labrousse VF et al. Short-term 
long chain omega3 diet protects from 
neuroinflammatory processes and 
memory impairment in aged mice. PLoS 
ONE. 2012;7(5):e36861
[73] Boudrault C, Bazinet RP, Kang 
JX, Ma DW. Cyclooxygenase-2 and 
n-6 PUFA are lower and DHA is 
higher in the cortex of fat-1 mice. 
Neurochemistry International. Mar. 
2010;56(4):585-589
[74] Bousquet M et al. Transgenic 
conversion of omega-6 into omega-3 
fatty acids in a mouse model of 
Parkinson’s disease. Journal of Lipid 
Research. Feb. 2011;52(2):263-271
[75] He C, Qu X, Cui L, Wang J, 
Kang JX. Improved spatial learning 
17
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
performance of fat-1 mice is associated 
with enhanced neurogenesis and 
neuritogenesis by docosahexaenoic acid. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. Jul. 2009;106(27):11370-11375
[76] Orr SK, Tong JY, Kang JX, Ma DW, 
Bazinet RP. The fat-1 mouse has brain 
docosahexaenoic acid levels achievable 
through fish oil feeding. Neurochemical 
Research. May 2010;35(5):811-819
[77] Delpech J-C et al. Transgenic 
increase in n-3/n-6 fatty acid ratio 
protects against cognitive deficits 
induced by an immune challenge 
through decrease of neuroinflammation. 
Neuropsychopharmacology. Feb. 
2015;40(3):525-536
[78] Bowen RA, Clandinin MT. Maternal 
dietary 22:6n-3 is more effective than 
18nn:3n-3 in increasing the 22:6n-3 
content in phospholipids of glial 
cells from neonatal rat brain. The 
British Journal of Nutrition. May 
2005;93(5):601-611
[79] Destaillats F et al. Differential effect 
of maternal diet supplementation with 
alpha-linolenic acid or n-3 long-chain 
polyunsaturated fatty acids on glial 
cell phosphatidylethanolamine and 
phosphatidylserine fatty acid profile 
in neonate rat brains. Nutrition & 
Metabolism (London). Jan. 2010;7:2
[80] Layé S. Polyunsaturated fatty 
acids, neuroinflammation and well 
being. Prostaglandins, Leukotrienes, 
and Essential Fatty Acids. Jun. 
2010;82(4-6):295-303
[81] Calder PC. Dietary modification 
of inflammation with lipids. The 
Proceedings of the Nutrition Society. 
Aug. 2002;61(3):345-358
[82] Sperling RI, Benincaso AI, 
Knoell CT, Larkin JK, Austen KF, 
Robinson DR. Dietary omega-3 
polyunsaturated fatty acids inhibit 
phosphoinositide formation and 
chemotaxis in neutrophils. The 
Journal of Clinical Investigation. Feb. 
1993;91(2):651-660
[83] P. Needleman, A. Raz, M. S. Minkes, 
J. A. Ferrendelli, and H. Sprecher 
Triene prostaglandins: Prostacyclin and 
thromboxane biosynthesis and unique 
biological properties. Proceedings of 
the National Academy of Sciences of the 
United States of America, vol. 76, no. 2, 
pp. 944-948, Feb. 1979
[84] Obata T, Nagakura T, Masaki 
T, Maekawa K, Yamashita 
K. Eicosapentaenoic acid inhibits 
prostaglandin D2 generation by 
inhibiting cyclo-oxygenase-2 in 
cultured human mast cells. 
Clinical and Experimental Allergy. 
1999;29(8):1129-1135
[85] Calder PC. n-3 fatty acids, 
inflammation and immunity: New 
mechanisms to explain old actions. The 
Proceedings of the Nutrition Society. 
Aug. 2013;72(3):326-336
[86] Headland SE, Norling LV. The 
resolution of inflammation: 
Principles and challenges. Seminars in 
Immunology. May 2015;27(3):149-160
[87] Serhan CN, Chiang N. Resolution 
phase lipid mediators of inflammation: 
Agonists of resolution. Current 
Opinion in Pharmacology. Aug. 
2013;13(4):632-640
[88] Serhan CN et al. Resolvins: A 
family of bioactive products of omega-3 
fatty acid transformation circuits 
initiated by aspirin treatment that 
counter proinflammation signals. The 
Journal of Experimental Medicine. Oct. 
2002;196(8):1025-1037
[89] Serhan CN, Chiang N, Van Dyke 
TE. Resolving inflammation: Dual 
anti-inflammatory and pro-resolution 
lipid mediators. Nature Reviews. 
Immunology. May 2008;8(5):349-361
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
18
[90] Shalini S-M et al. Distribution 
of Alox15 in the rat brain and its 
role in prefrontal cortical resolvin 
D1 formation and spatial working 
memory. Molecular Neurobiology. 
2018;55(2):1537-1550
[91] Nadjar A et al. NFkappaB activates 
in vivo the synthesis of inducible 
Cox-2 in the brain. Journal of Cerebral 
Blood Flow and Metabolism. Aug. 
2005;25(8):1047-1059
[92] Navarro-Mabarak C, Camacho-
Carranza R, Espinosa-Aguirre 
JJ. Cytochrome P450 in the central 
nervous system as a therapeutic target 
in neurodegenerative diseases. Drug 
Metabolism Reviews. 2018;50(2):95-108
[93] Czapski GA, Gajkowska 
B, Strosznajder JB. Systemic 
administration of lipopolysaccharide 
induces molecular and morphological 
alterations in the hippocampus. Brain 
Research. Oct. 2010;1356:85-94
[94] Schwab JM, Chiang N, Arita 
M, Serhan CN. Resolvin E1 and 
protectin D1 activate inflammation-
resolution programmes. Nature. Jun. 
2007;447(7146):869-874
[95] Pratico D et al. 12/15-lipoxygenase 
is increased in Alzheimer’s disease: 
Possible involvement in brain oxidative 
stress. The American Journal of 
Pathology. May 2004;164(5):1655-1662
[96] Wang X et al. Resolution of 
inflammation is altered in Alzheimer’s 
disease. Alzheimer's & Dementia. Jan. 
2015;11(1):40-50 e1-2
[97] Yigitkanli K, Zheng Y, Pekcec 
A, Lo EH, van Leyen K. Increased 
12/15-lipoxygenase leads to widespread 
brain injury following global cerebral 
ischemia. Translational Stroke Research. 
Apr. 2017;8(2):194-202
[98] Sun L, Xu YW, Han J, Liang H, 
Wang N, Cheng Y. 12/15-Lipoxygenase 
metabolites of arachidonic acid 
activate PPARgamma: A possible 
neuroprotective effect in ischemic 
brain. Journal of Lipid Research. Mar. 
2015;56(3):502-514
[99] Bystrom J et al. Endogenous 
epoxygenases are modulators of 
monocyte/macrophage activity. PLoS 
One. 2011;6(10):e26591
[100] Fleming I. Cytochrome P450-
dependent eicosanoid production 
and crosstalk. Current Opinion in 
Lipidology. Oct. 2011;22(5):403-409
[101] Gilroy DW et al. CYP450-derived 
oxylipins mediate inflammatory 
resolution. Proceedings of the 
National Academy of Sciences of 
the United States of America. Jun. 
2016;113(23):E3240-E3249
[102] Nebert DW, Wikvall K, Miller 
WL. Human cytochromes P450 in 
health and disease. Philosophical 
Transactions of the Royal Society of 
London. Series B, Biological Sciences. 
2013;368(1612):20120431
[103] Levi G, Minghetti L, Aloisi 
F. Regulation of prostanoid 
synthesis in microglial cells and 
effects of prostaglandin E2 on 
microglial functions. Biochimie. Nov. 
1998;80(11):899-904
[104] Farooqui AA, Horrocks 
LA, Farooqui T. Modulation of 
inflammation in brain: A matter of 
fat. Journal of Neurochemistry. May 
2007;101(3):577-599
[105] Meyer RP, Gehlhaus M, Knoth 
R, Volk B. Expression and function 
of cytochrome p450 in brain drug 
metabolism. Current Drug Metabolism. 
May 2007;8(4):297-306
[106] Volk B, Hettmannsperger U, 
Papp T, Amelizad Z, Oesch F, Knoth 
R. Mapping of phenytoin-inducible 
cytochrome P450 immunoreactivity 
19
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
in the mouse central nervous system. 
Neuroscience. 1991;42(1):215-235
[107] Barden AE, Mas E, Mori TA. 
n-3 Fatty acid supplementation 
and proresolving mediators of 
inflammation. Current Opinion in 
Lipidology. Feb. 2016;27(1):26-32
[108] Halade GV, Black LM, Verma 
MK. Paradigm shift—Metabolic 
transformation of docosahexaenoic and 
eicosapentaenoic acids to bioactives 
exemplify the promise of fatty acid drug 
discovery. Biotechnology Advances. 
Aug. 2018;36(4):935-953
[109] Recchiuti A. Resolvin D1 and 
its GPCRs in resolution circuits of 
inflammation. Prostaglandins & Other 
Lipid Mediators. Dec. 2013;107:64-76
[110] Sun YP et al. Resolvin D1 and 
its aspirin-triggered 17R epimer. 
Stereochemical assignments, anti-
inflammatory properties, and 
enzymatic inactivation. The Journal 
of Biological Chemistry. Mar. 
2007;282(13):9323-9334
[111] Mulik RS, Bing C, Ladouceur-
Wodzak M, Munaweera I, Chopra R, 
Corbin IR. Localized delivery of low-
density lipoprotein docosahexaenoic 
acid nanoparticles to the rat brain using 
focused ultrasound. Biomaterials. Mar. 
2016;83:257-268
[112] Sun W et al. Endogenous 
expression pattern of resolvin D1 in 
a rat model of self-resolution of 
lipopolysaccharide-induced acute 
respiratory distress syndrome 
and inflammation. International 
Immunopharmacology. Nov. 
2014;23(1):247-253
[113] Bisicchia E et al. Resolvin D1 
halts remote neuroinflammation 
and improves functional recovery 
after focal brain damage via ALX/
FPR2 receptor-regulated microRNAs. 
Molecular Neurobiology. Aug. 
2018;55(8):6894-6905
[114] Fredman G, Serhan 
CN. Specialized proresolving mediator 
targets for RvE1 and RvD1 in peripheral 
blood and mechanisms of resolution. 
The Biochemical Journal. Jul. 
2011;437(2):185-197
[115] Krishnamoorthy S, Recchiuti 
A, Chiang N, Fredman G, 
Serhan CN. Resolvin D1 receptor 
stereoselectivity and regulation 
of inflammation and proresolving 
microRNAs. The American Journal of 
Pathology. May 2012;180(5):2018-2027
[116] Recchiuti A, Krishnamoorthy 
S, Fredman G, Chiang N, Serhan 
CN. MicroRNAs in resolution of acute 
inflammation: Identification of novel 
resolvin D1-miRNA circuits. The FASEB 
Journal. Feb. 2011;25(2):544-560
[117] Rey C et al. Resolvin D1 and E1 
promote resolution of inflammation in 
microglial cells in vitro. Brain, Behavior, 
and Immunity. Jul. 2016;55:249-259
[118] Aursnes M et al. Total synthesis 
of the lipid mediator PD1n-3 DPA: 
Configurational assignments and 
anti-inflammatory and pro-resolving 
actions. Journal of Natural Products. 
Apr. 2014;77(4):910-916
[119] Doyle R, Sadlier DM, Godson 
C. Pro-resolving lipid mediators: 
Agents of anti-ageing? Seminars in 
Immunology. 2018;40:36-48
[120] Hong S, Gronert K, Devchand 
PR, Moussignac RL, Serhan CN. Novel 
docosatrienes and 17S-resolvins 
generated from docosahexaenoic acid in 
murine brain, human blood, and glial 
cells. Autacoids in anti-inflammation. 
The Journal of Biological Chemistry. 
2003;278(17):14677-14687
[121] Kuda O. Bioactive metabolites of 
docosahexaenoic acid. Biochimie. May 
2017;136:12-20
[122] Marcheselli VL et al. Novel 
docosanoids inhibit brain 
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
20
ischemia-reperfusion-mediated 
leukocyte infiltration and pro-
inflammatory gene expression. The 
Journal of Biological Chemistry. Oct. 
2003;278(44):43807-43817
[123] Lukiw WJ et al. A role for 
docosahexaenoic acid-derived 
neuroprotectin D1 in neural cell 
survival and Alzheimer disease. The 
Journal of Clinical Investigation. Oct. 
2005;115(10):2774-2783
[124] Bazan NG et al. Novel aspirin-
triggered neuroprotectin D1 attenuates 
cerebral ischemic injury after 
experimental stroke. Experimental 
Neurology. Jul. 2012;236(1):122-130
[125] Yao C, Zhang J, Chen F, Lin 
Y. Neuroprotectin D1 attenuates 
brain damage induced by transient 
middle cerebral artery occlusion in 
rats through TRPC6/CREB pathways. 
Molecular Medicine Reports. Aug. 
2013;8(2):543-550
[126] Serhan CN et al. Maresins: Novel 
macrophage mediators with potent 
antiinflammatory and proresolving 
actions. The Journal of Experimental 
Medicine. Jan. 2009;206(1):15-23
[127] Zhu M et al. Pro-resolving lipid 
mediators improve neuronal survival 
and increase Abeta42 phagocytosis. 
Molecular Neurobiology. May 
2016;53(4):2733-2749
[128] Xian W et al. The pro-
resolving lipid mediator Maresin 1 
protects against cerebral ischemia/
reperfusion injury by attenuating 
the pro-inflammatory response. 
Biochemical and Biophysical 
Research Communications. Mar. 
2016;472(1):175-181
[129] Xian W, Li T, Li L, Hu L, Cao J.  
Maresin 1 attenuates the inflammatory 
response and mitochondrial damage in 
mice with cerebral ischemia/reperfusion 
in a SIRT1-dependent manner. Brain 
Research. 2019
[130] Francos-Quijorna I et al. Maresin 
1 promotes inflammatory resolution, 
neuroprotection, and functional 
neurological recovery after spinal cord 
injury. The Journal of Neuroscience. 
Nov. 2017;37(48):11731-11743
[131] Ohira T, Arita M, Omori K, 
Recchiuti A, Van Dyke TE, Serhan 
CN. Resolvin E1 receptor activation 
signals phosphorylation and 
phagocytosis. The Journal of Biological 
Chemistry. Jan. 2010;285(5):3451-3461
[132] Isobe Y et al. Identification and 
structure determination of novel anti-
inflammatory mediator resolvin E3, 
17,18-dihydroxyeicosapentaenoic acid. 
The Journal of Biological Chemistry. 
Mar. 2012;287(13):10525-10534
[133] Chen CT, Liu Z, Bazinet RP.  
Rapid de-esterification and loss 
of eicosapentaenoic acid from 
rat brain phospholipids: An 
intracerebroventricular study. 
Journal of Neurochemistry. Feb. 
2011;116(3):363-373
[134] Siegert E, Paul F, Rothe M, 
Weylandt KH. The effect of omega-3 
fatty acids on central nervous system 
remyelination in fat-1 mice. BMC 
Neuroscience. 2017;18(1):19
[135] Krishnamoorthy S et al. Resolvin 
D1 binds human phagocytes with 
evidence for proresolving receptors. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. Jan. 2010;107(4):1660-1665
[136] Arita M, Ohira T, Sun YP, 
Elangovan S, Chiang N, Serhan CN.  
Resolvin E1 selectively interacts with 
leukotriene B4 receptor BLT1 and 
ChemR23 to regulate inflammation. 
Journal of Immunology. Mar. 
2007;178(6):3912-3917
21
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
[137] Ho CF-Y et al. Localisation of 
formyl-peptide receptor 2 in the rat 
central nervous system and its role 
in axonal and dendritic outgrowth. 
Neurochemical Research. Aug. 
2018;43(8):1587-1598
[138] Guo X et al. Chronic mild 
restraint stress rats decreased 
CMKLR1 expression in distinct brain 
region. Neuroscience Letters. Aug. 
2012;524(1):25-29
[139] Graham KL et al. Chemokine-like 
receptor-1 expression by central nervous 
system-infiltrating leukocytes and 
involvement in a model of autoimmune 
demyelinating disease. Journal of 
Immunology. 2009;183(10):6717-6723
[140] Xu ZZ et al. Resolvins RvE1 and 
RvD1 attenuate inflammatory pain via 
central and peripheral actions. Nature 
Medicine. May 2010;16(5):592-597, 1p 
following 597
[141] Qu L, Caterina MJ. Accelerating 
the reversal of inflammatory pain with 
NPD1 and its receptor GPR37. The 
Journal of Clinical Investigation. Aug. 
2018;128(8):3246-3249
[142] Colas RA, Shinohara M, Dalli J, 
Chiang N, Serhan CN. Identification 
and signature profiles for pro-resolving 
and inflammatory lipid mediators 
in human tissue. American Journal 
of Physiology-Cell Physiology. Jul. 
2014;307(1):C39-C54
[143] Serhan CN, Chiang N, Dalli J. New 
pro-resolving n-3 mediators bridge 
resolution of infectious inflammation to 
tissue regeneration. Molecular Aspects 
of Medicine. Dec. 2018;64:1-17
[144] Famenini S et al. Increased 
intermediate M1-M2 macrophage 
polarization and improved cognition in 
mild cognitive impairment patients on 
omega-3 supplementation. The FASEB 
Journal. Jan. 2017;31(1):148-160
[145] Mizwicki MT et al. 1alpha,25-
dihydroxyvitamin D3 and resolvin D1 
retune the balance between amyloid-
beta phagocytosis and inflammation 
in Alzheimer’s disease patients. 
Journal of Alzheimer's Disease. 
2013;34(1):155-170
[146] Uno H et al. Immunonutrition 
suppresses acute inflammatory 
responses through modulation of 
resolvin E1 in patients undergoing 
major hepatobiliary resection. Surgery. 
2016;160(1):228-236
[147] Hiram R et al. Resolvin E1 
normalizes contractility, Ca2+ sensitivity 
and smooth muscle cell migration 
rate in TNF-α- and IL-6-pretreated 
human pulmonary arteries. American 
Journal of Physiology. Lung Cellular 
and Molecular Physiology. Oct. 
2015;309(8):L776-L788
[148] Gyurko R, Van Dyke TE. The 
role of polyunsaturated ω-3 fatty acid 
eicosapentaenoic acid-derived resolvin 
E1 (RvE1) in bone preservation. 
Critical Reviews in Immunology. 
2014;34(4):347-357
[149] Abdelmoaty S et al. Spinal actions 
of lipoxin A4 and 17(R)-resolvin D1 
attenuate inflammation-induced 
mechanical hypersensitivity and 
spinal TNF release. PLoS One. 
2013;8(9):e75543
[150] Rossi S et al. Protection from 
endotoxic uveitis by intravitreal resolvin 
D1: Involvement of lymphocytes, 
miRNAs, ubiquitin-proteasome, and 
M1/M2 macrophages. Mediators of 
Inflammation. 2015;2015:149381
[151] Titos E et al. Resolvin D1 and 
its precursor docosahexaenoic acid 
promote resolution of adipose tissue 
inflammation by eliciting macrophage 
polarization toward an M2-like 
phenotype. Journal of Immunology. 
Nov. 2011;187(10):5408-5418
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
22
[152] Li L et al. Resolvin D1 promotes 
the interleukin-4-induced alternative 
activation in BV-2 microglial cells. 
Journal of Neuroinflammation. 
2014;11:72
[153] Kantarci A et al. Combined 
administration of resolvin E1 and 
lipoxin A4 resolves inflammation 
in a murine model of Alzheimer’s 
disease. Experimental Neurology. 
2018;300:111-120
[154] Harrison JL et al. Resolvins AT-D1 
and E1 differentially impact functional 
outcome, post-traumatic sleep, 
and microglial activation following 
diffuse brain injury in the mouse. 
Brain, Behavior, and Immunity. Jul. 
2015;47:131-140
[155] Xu MX et al. Resolvin D1, 
an endogenous lipid mediator for 
inactivation of inflammation-related 
signaling pathways in microglial 
cells, prevents lipopolysaccharide-
induced inflammatory responses. CNS 
Neuroscience & Therapeutics. Apr. 
2013;19(4):235-243
[156] Terrando N et al. Aspirin-triggered 
resolvin D1 prevents surgery-induced 
cognitive decline. The FASEB Journal. 
Sep. 2013;27(9):3564-3571
[157] Luo C et al. Enriched endogenous 
omega-3 fatty acids in mice protect 
against global ischemia injury. 
Journal of Lipid Research. Jul. 
2014;55(7):1288-1297
[158] Furuyashiki T, Akiyama S, Kitaoka 
S. Roles of multiple lipid mediators in 
stress and depression. International 
Immunology. 2019
[159] Deyama S et al. Resolvin D1 
and D2 reverse lipopolysaccharide-
induced depression-like behaviors 
through the mTORC1 signaling 
pathway. The International Journal 
of Neuropsychopharmacology. Jul. 
2017;20(7):575-584
[160] Deyama S et al. Resolvin E1/
E2 ameliorate lipopolysaccharide-
induced depression-like behaviors 
via ChemR23. Psychopharmacology. 
2018;235(1):329-336
[161] Deyama S, Shimoda K, Ikeda H, 
Fukuda H, Shuto S, Minami M. Resolvin 
E3 attenuates lipopolysaccharide-
induced depression-like behavior 
in mice. Journal of Pharmacological 
Sciences. Sep. 2018;138(1):86-88
[162] Klein CP, Sperotto ND, Maciel 
IS, Leite CE, Souza AH, Campos 
MM. Effects of D-series resolvins 
on behavioral and neurochemical 
changes in a fibromyalgia-like model 
in mice. Neuropharmacology. Nov. 
2014;86:57-66
[163] Gilbert K, Bernier J, Godbout R, 
Rousseau G. Resolvin D1, a metabolite 
of omega-3 polyunsaturated fatty 
acid, decreases post-myocardial 
infarct depression. Marine Drugs. Nov. 
2014;12(11):5396-5407
[164] Ishikawa Y et al. Rapid and 
sustained antidepressant effects 
of resolvin D1 and D2 in a chronic 
unpredictable stress model. Behavioural 
Brain Research. Aug. 2017;332:233-236
[165] Zhu M, Wang X, Schultzberg M, 
Hjorth E. Differential regulation of 
resolution in inflammation induced by 
amyloid-β42 and lipopolysaccharides in 
human microglia. Journal of Alzheimer's 
Disease. 2015;43(4):1237-1250
[166] Tian Y, Zhang Y, Zhang R, Qiao S, 
Fan J. Resolvin D2 recovers neural injury 
by suppressing inflammatory mediators 
expression in lipopolysaccharide-
induced Parkinson’s disease rat 
model. Biochemical and Biophysical 
Research Communications. May 
2015;460(3):799-805
[167] Shevalye H et al. Effect of 
enriching the diet with menhaden oil 
or daily treatment with resolvin D1 on 
23
Polyunsaturated Fatty Acid Metabolism in the Brain and Brain Cells
DOI: http://dx.doi.org/10.5772/intechopen.88232
neuropathy in a mouse model of type 2 
diabetes. Journal of Neurophysiology. 
Jul. 2015;114(1):199-208
[168] Hashimoto M et al. n-3 fatty 
acids effectively improve the 
reference memory-related learning 
ability associated with increased 
brain docosahexaenoic acid-
derived docosanoids in aged rats. 
Biochimica et Biophysica Acta. Feb. 
2015;1851(2):203-209
[169] Taha AY et al. Regulation of rat 
plasma and cerebral cortex oxylipin 
concentrations with increasing levels 
of dietary linoleic acid. Prostaglandins, 
Leukotrienes & Essential Fatty Acids. 2016
[170] Ostermann AI et al. A diet rich in 
omega-3 fatty acids enhances expression 
of soluble epoxide hydrolase in murine 
brain. Prostaglandins & Other Lipid 
Mediators. Nov. 2017;133:79-87
[171] Farias SE, Basselin M, Chang L, 
Heidenreich KA, Rapoport SI, Murphy 
RC. Formation of eicosanoids, E2/D2 
isoprostanes, and docosanoids following 
decapitation-induced ischemia, 
measured in high-energy-microwaved 
rat brain. Journal of Lipid Research. 
Sep. 2008;49(9):1990-2000
[172] Yang G, Pan F, Gan WB. Stably 
maintained dendritic spines are 
associated with lifelong memories. 
Nature. Dec. 2009;462(7275):920-924
[173] Balvers MG et al. Fish oil and 
inflammatory status alter the n-3 to 
n-6 balance of the endocannabinoid 
and oxylipin metabolomes in mouse 
plasma and tissues. Metabolomics. Dec. 
2012;8(6):1130-1147
[174] Willenberg I, Rund K, Rong 
S, Shushakova N, Gueler F, Schebb 
NH. Characterization of changes 
in plasma and tissue oxylipin levels 
in LPS and CLP induced murine 
sepsis. Inflammation Research. Feb. 
2016;65(2):133-142
[175] Rosenberger TA et al. 
Rat brain arachidonic acid 
metabolism is increased by a 6-day 
intracerebral ventricular infusion 
of bacterial lipopolysaccharide. 
Journal of Neurochemistry. Mar. 
2004;88(5):1168-1178
[176] Taha AY et al. Dietary 
linoleic acid lowering reduces 
lipopolysaccharide-induced increase 
in brain arachidonic acid metabolism. 
Molecular Neurobiology. Aug. 
2017;54(6):4303-4315
[177] Dieter P, Scheibe R, Kamionka S, 
Kolada A. LPS-induced synthesis and 
release of PGE2 in liver macrophages: 
Regulation by CPLA2, COX-1, COX-
2, and PGE2 synthase. Advances in 
Experimental Medicine and Biology. 
2002;507:457-462
[178] Le Faouder P et al. LC-MS/MS 
method for rapid and concomitant 
quantification of pro-inflammatory  
and pro-resolving polyunsaturated  
fatty acid metabolites. Journal  
of Chromatography. B, Analytical 
Technologies in the Biomedical  
and Life Sciences. Aug. 
2013;932:123-133
[179] Slepko N, Minghetti L,  
Polazzi E, Nicolini A, Levi 
G. Reorientation of prostanoid 
production accompanies ‘activation’ of 
adult microglial cells in culture. Journal 
of Neuroscience Research.  
Aug. 1997;49(3):292-300
[180] Wang C, Wang M, Zhou Y, Dupree 
JL, Han X. Alterations in mouse brain 
lipidome after disruption of CST 
gene: A lipidomics study. Molecular 
Neurobiology. Aug. 2014;50(1):88-96
[181] Jung YS et al. Probucol  
inhibits LPS-induced microglia 
activation and ameliorates 
brain ischemic injury in normal 
and hyperlipidemic mice. Acta 
Pharmacologica Sinica. Aug. 
2016;37(8):1031-1044
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
24
[182] Kim HW, Rao JS, Rapoport 
SI, Igarashi M. Dietary n-6 PUFA 
deprivation downregulates arachidonate 
but upregulates docosahexaenoate 
metabolizing enzymes in rat brain. 
Biochimica et Biophysica Acta. Feb. 
2011;1811(2):111-117
